IBA partners with Jubilant Radiopharma, selling five Cyclone® KIUBE to support their PET radioisotope production across the US
Louvain-la-Neuve, Belgium and Yardley, Pennsylvania, USA, October 29 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, and Jubilant Radiopharma, a business segment of Jubilant Pharmova Limited with the second largest network of Radiopharmacies in the United States (U.S.), are pleased to announce the signing of a contract for the installation of five Cyclone® KIUBE 180 cyclotrons and associated equipment in the U.S.
The contract will support Jubilant Radiopharma’s initial $50 million (USD) positron emission tomography (PET) radiopharmaceutical manufacturing network expansion plan. This investment, combined with the addition of the IBA RadioPharma Solutions equipment, will greatly expand Jubilant Radiopharma’s capacity to produce and distribute cGMP compliant PET radiotracers across the U.S., with a particular focus in the care areas of oncology, urology, cardiology, and neurology.
The cyclotrons will be installed at Jubilant Radiopharma’s PET manufacturing facilities located strategically across the U.S., bringing its total number of PET manufacturing facilities to nine. Each of the five locations will be equipped with IBA’s Cyclone® KIUBE 180 cyclotron, self-shielding and targets.
The Cyclone® KIUBE is one of the most advanced cyclotrons available. It is known for its upgradability, compact design, high efficiency, and the ability to produce a wide variety of radioisotopes, making it ideal for both research and commercial production. The Cyclone® KIUBE is well-suited for producing a wide range of PET radioisotopes including Fluorine 18, Gallium 68, Zirconium 89, Carbon 11, and others, used in the diagnosis and monitoring of various medical conditions including cancer and neurological disorders.
The typical price range for a Cyclone® KIUBE and related equipment is from EUR two and a half to five million, depending on the options and configuration.
Charles Kumps, President of IBA RadioPharma Solutions, commented:“IBA is proud to enter into this agreement with Jubilant Radiopharma to support the expansion of their radiopharmaceuticals production network in PET. This first contract demonstrates IBA's industry-leading radiopharmaceutical offering. Our cutting-edge solutions and our expertise to integrate all necessary equipment for a fully GMP compliant radiopharmacy, will accelerate Jubilant Radiopharma’s expansion in all PET radioisotopes to advance nuclear medicine in US.”
Harsher Singh, CEO of Jubilant Radiopharma, stated: “Partnering with IBA and selecting their high energy dual beam cyclotron will enable Jubilant Radiopharma to increase production capacity and serve patients across the U.S. with a variety of PET radiotracers during peak hours when they need them most.”